Drug intelligence / Profile preview

eOPN3

Development stage: Preclinical
Modality: Gene Therapies
Administration: Intracerebral

Overview

eOPN3 is a red-shifted, inhibitory type-2 opsin derived from encephalopsin (OPN3), a G protein-coupled receptor (GPCR). It is utilized as an optogenetic tool for precise neuromodulation. When expressed in neurons (often via viral vectors like AAV) and activated by light, eOPN3 triggers the Gi/o signaling pathway, leading to the suppression of synaptic transmission and neuronal activity. This inhibitory effect is being investigated for the treatment of drug-resistant focal epilepsies, such as mesial temporal lobe epilepsy (mTLE), by modulating complex epilepsy networks like the hippocampus-anterior nucleus of the thalamus (HPC-ANT) circuit.

Other names: encephalopsinAAV5/9-CaMKII-eOPN3-mScarlet

Targets

CaV (Voltage-gated calcium channel protein complex)Gi/o (G protein subunit alpha i/o family)11-cis-Retinal

Beyond the preview

Go deeper on eOPN3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eOPN3.

Explore the full profile